Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

Duvelisib is an oral dual inhibitor of phosphoinositide 3-kinase-δ (PI3K-δ) and PI3K-γ in late-stage clinical development for hematologic malignancy treatment. This phase 1 study evaluated maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics (PD), efficacy, and safety of duvelisib in 210...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Flinn, Ian W., O’Brien, Susan, Kahl, Brad, Patel, Manish, Oki, Yasuhiro, Foss, Francine F., Porcu, Pierluigi, Jones, Jeffrey, Burger, Jan A., Jain, Nitin, Kelly, Virginia M., Allen, Kerstin, Douglas, Mark, Sweeney, Jennifer, Kelly, Patrick, Horwitz, Steven
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2018
Matèries:
Lymphoid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6033052/
https://ncbi.nlm.nih.gov/pubmed/29191916
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-05-786566
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars